[Clinical study of a synthetic anti-parkinsonian drug, akinophyl (or 2-piperidino-1-phenyl-bicycloheptenyl-propanol chlorhydrate)].
D000433:1-Propanol / Q000627:therapeutic use*; D000328:Adult; D000367:Age Factors; D000368:Aged; D001714:Bipolar Disorder / Q000188:drug therapy*; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009461:Neurologic Manifestations; D010300:Parkinson Disease / Q000188:drug therapy*; D010880:Piperidines / Q000627:therapeutic use*; D011618:Psychotic Disorders / Q000188:drug therapy*; D012559:Schizophrenia / Q000188:drug therapy*; D014149:Tranquilizing Agents / Q000009:adverse effects*
D010880:Piperidines; D014149:Tranquilizing Agents; D000433:1-Propanol
Etude clinique d'un anti-parkinsonien de synthèse l'akinophyl (ou chlorhydrate de 3-pipéridino-1-phényl-1-bicycloheptényl-propanol)